Where does British Columbia Cancer Agency Branch rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), British Columbia Cancer Agency Branch ranks #6,628 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does British Columbia Cancer Agency Branch hold?

British Columbia Cancer Agency Branch holds 50 US utility patents granted between 2015 and 2024, spanning 26 technology areas.

What is British Columbia Cancer Agency Branch's Innovation Score?

British Columbia Cancer Agency Branch has an Innovation Score of 48.5 out of 100 (top 17% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does British Columbia Cancer Agency Branch focus on?

British Columbia Cancer Agency Branch's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 23 patents, ranking #848 of 6,058 assignees active in that subclass. Grants appear in 26 CPC subclasses total.

Is British Columbia Cancer Agency Branch's patent grant rate increasing or decreasing?

British Columbia Cancer Agency Branch's recent grant velocity is -39% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for British Columbia Cancer Agency Branch's patents?

British Columbia Cancer Agency Branch's patents average 20.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the British Columbia Cancer Agency Branch patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

British Columbia Cancer Agency Branch

USPTO PatentsView assignee record - 50 granted patents across 26 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, British ranks #6,628 of 49,997 tracked US assignees by granted-patent volume, with 50 patents across 26 technology areas.

#6,628
of 49,997 US assignees by volume: Top 17%
by Innovation Score (48.5/100): 20.9
avg claims per patent: -39%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R6628 · Foreign Corporation #6,628 · 50 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-DENSE · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL

GRANTS-SMALL 50 grants
UPPER-Q #6,628/49,997
PHOTO-FINISH Barrette Outdoor…
CPC-FOCUS A61P · 26 areas
INNOV-PAR 48.5/100
CLAIMS-DENSE 20.9 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DOWN -39% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Barrette Outdoor Living, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How British’s 48.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 13.6 pts (28%) Velocity 4.3 pts (9%) Breadth 18.0 pts (37%) Claim depth 12.6 pts (26%)

Qualcomm Incorporated · highest

85
17live Japan · near

48
Asus Technology… · near

48
British Columbia… · this assignee

48
National ICT Australia · near

48
Siemens Mobility… · near

48
3D Lighting… · lowest

7

What this shows British's Innovation Score is 48.5/100 (top 17% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for British?

Each dot is one of British’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). British’s own 20.9 claims/patent is ABOVE the 13.6 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

British vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where British's grants concentrate

British Columbia Cancer Agency Branch is a focused PatentsView assignee: 26 CPC subclasses with 46% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2017 (9 grants) versus a trough of 2 in 2024. By volume, British sits between Beijing Youzhuju Network Technology Co., Ltd. and Chipbond Technology Corporation.

British's three-year grant acceleration

British Columbia Cancer Agency Branch shows 9 grants in 2022–2024 against only 14 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Beijing Youzhuju…

50
Barrette Outdoor…

50
Beigene

50
Bradford

50
Central Garden &…

50
Chdi Foundation

50
Chinese Research…

50
Chipbond Technolo…

50
British Columbia… ◀

50

What this shows British holds 50 patents at rank #6,628, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near British

By rank, the assignees closest to #6,628 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in British's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for British, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), British ranks #848 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (48 here).

National ICT Australia Limited 48 Siemens Mobility Austria GmbH 48 Asus Technology Licensing Inc. 48 17live Japan Inc. 48

Similar claim depth

Nearest assignees by average claims per patent (20.9 here).

Incept, LLC 20.9 avg Analog Photonics LLC 20.9 avg STMicroelectronics (Rousset) SAS 20.9 avg Earlens Corporation 20.9 avg

British's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

48 Top 17% higher than 83% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

British Columbia Cancer Agency Branch patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	6	12.0%
2016	4	8.0%
2017	9	18.0%
2018	8	16.0%
2019	4	8.0%
2020	6	12.0%
2021	4	8.0%
2022	4	8.0%
2023	3	6.0%
2024	2	4.0%

Which technologies does British Columbia Cancer Agency Branch patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 23

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 21

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 19

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 13

A61B - DIAGNOSIS; SURGERY; Identification 12

C07D - Heterocyclic Compounds 9

C07K - Peptides 7

C07C - Acyclic OR Carbocyclic Compounds 6

G16B - Bioinformatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR Genetic OR Protein-related Data Processing IN Computational Molecular Biology 5

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 5

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 5

G02B - Optical Elements, Systems OR Apparatus 3

B23B - TURNING; Boring 2

F16D - Couplings FOR Transmitting ROTATION; CLUTCHES; Brakes 2

Y02A - Technologies FOR Adaptation TO Climate Change 2

Top 15 of 26 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

British Columbia Cancer Agency Branch's patent record in context - here's where to go next.

British Columbia Cancer Agency Branch's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 46% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #6,628 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare British Columbia Cancer Agency Branch against Beijing Youzhuju Network Technology Co., Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 48.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.